About 200 reports

  • 5.3 FIRST-IN-CLASS PIPELINE PROGRAMS TARGETING NOVEL MOLECULAR TARGETS
  • Asthma Therapeutics Market, Global, Pipeline Programs Targeting CC Chemokine Receptor Type-3, 2016

In the case of allergic diseases, and possibly asthma, an imbalance between T-helper (Th) ## and Th## cytokines has been postulated (NHLBI, 2007).

  • Cytokine
  • World
  • Almirall, S.A.
  • Genentech, Inc.
  • Novartis AG

Global Laboratory Reagents Industry LABORATORY REAGENTS MCP-## A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS ##.

  • Cytokine
  • APAC
  • Japan
  • United States
  • World
  • 7.1 SEGMENTATION-BY CYTOKINE TYPE
  • Italian Cytokine Market in USD million, by Cytokine Type, 2014 to 2022

Cytokine Market In 2016, the global cytokine market was valued at USD XX million. Considering the historical trend and possible future developments, the market is projected to reach USD XX million by 2022, registering a CAGR of XX%, during 2017-2022 (the forecast period). Cytokines are a group of immune-mediators,...

  • Cytokine
  • North America
  • United States
  • World
  • Market Size
  • Interferon Major Producer and Their Market Share

The auto exports exceeded over ## million each year.

  • Cytokine
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.
  • Interleukin
  • Interleukin

The auto exports exceeded over ## million each year.

  • Cytokine
  • China
  • Demand
  • Harbin Pharmaceutical Group
  • North China Pharmaceutical Group Corp.
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H1 2016’, provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF...

  • Cytokine
  • Interleukin
  • Turkey
  • United States
  • Product Initiative
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products
  • Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF...

  • Cancer
  • Cytokine
  • United States
  • Product Initiative
  • ARMO Biosciences, Inc.
  • Rheumatoid Arthritis, Global, Pipeline by Molecular Target and Stage of Development, 2016
  • 4.3 EPIDEMIOLOGY

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs...

  • Arthritis
  • Cytokine
  • Pathology
  • World
  • Deals & Alliance
  • C) Pipeline breakdown of cytokine and cytokine receptors
  • 4.4.4 THE ROLE OF CYTOKINES

Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation Summary In 2015, more than of 125,000 transplantations were performed worldwide, an increase...

  • Cytokine
  • General Medicine And Specialty Medicine
  • Transplantation
  • World
  • Deals & Alliance
  • CYTOSORB - CYTOKINE ADSORPTION IN SEPSIS AND ACUTE KIDNEY INJURY
  • CYTOSORB - REMOVAL OF CYTOKINES DURING CARDIAC SURGERY

Blood Purification Equipment - Medical Devices Pipeline Assessment, 2018 Summary GlobalData’s Medical Devices sector report, “Blood Purification Equipment - Medical Devices Pipeline Assessment, 2018" provides an overview of Blood Purification Equipment currently in pipeline stage. The report...

  • Blood Supply
  • Clinical Trial
  • Cytokine
  • Hospital
  • CytoSorbents Corporation
  • 12.15 CYTOKINE RELEASE SYNDROME (CRS) WITH CART19 THERAPY
  • CYTOKINE RELEASE SYNDROME (CRS) WITH CART19 THERAPY

EXECUTIVE SUMMARY CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is the biggest breakthrough since the introduction of chemotherapy. Already two products (Kymriah and Yescarta) have been approved by the U.S. FDA and European EMA for different cancer indications.  What...

  • Cell Therapy
  • Cytokine
  • Motor Vehicle
  • Therapy
  • Novartis AG
  • SEP 13, 2017: BIONIZ THERAPEUTICS PRESENTS DATA DEMONSTRATING THE SYNERGISTIC EFFECTS OF CYTOKINES IL-15 AND IL-21 IN CELIAC DISEASE PATHOGENESIS
  • JAN 04, 2018: IMMUSANT PROVIDES YEAR-END UPDATE AND OUTLINES GOALS FOR 2018

Celiac Disease - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2018, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune...

  • Cytokine
  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative
  • DAROMUN - DRUG PROFILE

April ##, 2017, ##:## - ##:## p. m.

  • Cytokine
  • Therapy
  • United States
  • World
  • Product Initiative
  • FEB 03, 2017: NEOVACS ANNOUNCES INDEPENDENT DATA AND SAFETY MONITORING BOARD SUPPORTS CONTINUATION OF PHASE IIB CLINICAL TRIAL FOR IFNA KINOID IN LUPUS
  • DEC 07, 2016: NEOVACS OBTAINS FDA "FAST TRACK" DESIGNATION FOR IFNA KINOID IN LUPUS (SLE)

The JV will be governed by a three-member board of directors, two of whom will be appointed by Neovacs and one appointed by Stellar Biotech.

  • Cytokine
  • Healthcare
  • France
  • Company
  • Neovacs SA
  • R-191 - DRUG PROFILE
  • R&D Progress Research and Development Brief

Inhibition of IRAK blocks the TLR##- and IL-##R-induced cytokine production and elicits therapeutic activity.

  • Cytokine
  • Therapy
  • United States
  • World
  • Product Initiative

MARKET ##.

  • Biological Therapy
  • Cytokine
  • APAC
  • World
  • Company Sales
  • AN-4161 - DRUG PROFILE

GOUTVAX IS AN IL-## BETA, A PROINFLAMMATORY CYTOKINE CANDIDATE.

  • Chronic Disease
  • Cytokine
  • Therapy
  • United States
  • Product Initiative
  • C) Breakdown of cytokines/growth factors and receptors
  • Orphan and Rare Dermatological Diseases, Global,

Frontier Pharma: Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa Summary Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails....

  • Cytokine
  • Dermatological Condition
  • Pathology
  • World
  • Deals & Alliance
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles

The molecules developed by companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Biological Therapy
  • Cytokine
  • Therapy
  • World
  • Product Initiative
  • Target
  • Clinical Trial profile. 177 Trial Title

NC. ##. ## Central Nervous System Relapsing Remitting Multiple Sclerosis (RRMS) Completed Phase IV Interventional interferon beta-##b Lugano Regional Hospital - Civic ## Jun 2010 ## Nov 2011 ## ## ## ## ## Interferon Alpha/ Beta Receptor ## (Cytokine Receptor Class II Membe

  • Clinical Trial
  • Cytokine
  • Neurological Disorder
  • Therapy
  • Biogen Idec Inc.
  • MONOCLONAL ANTIBODY THAT BINDS SELECTIVELY TO INTERLEUKIN-1 BETA (IL-1 BETA), ONE OF THE INFLAMMATORY CYTOKINES, NEUTRALIZING ITS ACTIVITY.
  • SOBI-006 - DRUG PROFILE

Interleukin 1 (IL1) - Pipeline Review, H1 2018 Summary According to the recently published report ’Interleukin 1 (IL1) - Pipeline Review, H1 2018’; Interleukin 1 (IL1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining...

  • Cytokine
  • Hospital
  • Therapy
  • United States
  • Product Initiative
  • Target
  • Target

## (Cytokine Receptor Class II Member ## or Cytokine Receptor Family ## Member ## or Type I Interferon Receptor ## or IFNAR##) Agonist; Interferon Alpha/ Beta Receptor ## (Interferon Alpha Binding Protein or Type I Interferon Receptor ## or IFNAR##) A

  • Clinical Trial
  • Cytokine
  • Monoclonal Antibody
  • Neurological Disorder
  • Biogen Idec Inc.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database
  • Official Title

## ## Moerae Matrix Inc ## ## ## Linear Clinical Research Ltd ## ## ## GlaxoSmithKline Plc ## ## ## CSL Ltd ## ## ## CPR Pharma Services Pty Ltd ## ## ## Clinical Network Services (CNS) Pty Ltd ## ##

  • Clinical Trial
  • Cytokine
  • Drug Discovery And Development
  • World
  • Product Initiative
  • ORTHOMAB - DRUG PROFILE
  • R&D Progress Research and Development Brief

NO SEVERE CYTOKINE RELEASE SYNDROME (SCRS) WAS OBSERVED; ## PATIENTS HAD GRADE ##-## CRS (## RECEIVED TOCILIZUMAB).

  • Cytokine
  • Hospital
  • Lymphoma
  • Therapy
  • Juno Therapeutics Inc.
  • Clinical Trial profile. 171 Trial Title

Hoffmann-La Roche Ltd ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Gilead Sciences Inc ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## Bristol-M

  • Cancer
  • Cytokine
  • Leukemia
  • World
  • Product Initiative

When the drug candidate binds to the receptors, it blocks or modulates the actions of the cytokines responsible for neutrophil recruitment.

  • Breast Cancer
  • Cytokine
  • Therapy
  • Transplantation
  • Dompe Farmaceutici S.p.A.
  • Target

Merck KG ## ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## ## F.

  • Clinical Trial
  • Cytokine
  • Drug Discovery And Development
  • Neurological Disorder
  • Biogen Idec Inc.

When the drug candidate binds to the receptors, it blocks or modulates the actions of the cytokines responsible for neutrophil recruitment.

  • Breast Cancer
  • Cytokine
  • Therapy
  • Transplantation
  • Dompe Farmaceutici S.p.A.
  • Clinical Trial profile. 139 Trial Title
  • Clinical Trial profile. 333 Trial Title

This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases.

  • Autoimmune Disease
  • Cytokine
  • Therapy
  • World
  • Product Initiative
  • Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview
  • Mechanism Of Action

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted pipeline therapeutics. The...

  • Autoimmune Disease
  • Cytokine
  • World
  • Product Initiative
  • Novartis AG